At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 162 enrolled
Drug / intervention
A. CNS 7056 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb Study Evaluating the Safety and Efficacy of Multiple Doses of CNS 7056 Compared to Midazolam in Patients Undergoing Colonoscopy
In Brief
A Phase 2 clinical trial evaluating A. CNS 7056, B. CNS 7056, and 2 other interventions for Sedation. Completed, enrolled 162 participants across 9 sites.
Detailed Summary
The purpose of this dose-response study is to assess the safety and efficacy of CNS 7056 compared with midazolam to maintain suitable sedation levels in patients undergoing colonoscopy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSedation
CountriesUnited States
CollaboratorsPremier Research
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2010
Primary CompletionSep 2010
Study CompletionOct 2010
TodayJul 2026
First PostedJun 16, 2010
Enrollment StartMay 1, 2010
Primary CompletionSep 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.0 years ago
Interventions
A. CNS 7056drug
Initial low dose plus supplemental doses as necessary.
B. CNS 7056drug
Initial intermediate dose plus supplemental doses as necessary.
C. CNS 7056drug
Initial high dose plus supplemental doses as necessary.
D. Midazolamdrug
Initial standardized dose plus supplemental doses as necessary.